[{"orgOrder":0,"company":"Laboratorium Ofichem B.V","sponsor":"Entheon Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Laboratorium Ofichem B.V","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Laboratorium Ofichem B.V \/ Ofichem Laboratorium","highestDevelopmentStatusID":"7","companyTruncated":"Laboratorium Ofichem B.V \/ Ofichem Laboratorium"}]

Find Clinical Drug Pipeline Developments & Deals by Laboratorium Ofichem B.V

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Formulation and stability testing of DMT drug product by CHDR's partner pharmacy has commenced in accordance with projected start date of EBRX-101(N, N-dimethyltryptamine), a study that will evaluate controlled intravenous infusion of population of healt...

                          Brand Name : EBRX-101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 24, 2021

                          Lead Product(s) : Dimethyltryptamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Entheon Biomedical

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Ofichem Company Banner